Theravance Biopharma, Inc. Deferred Revenue
Theravance Biopharma, Inc. (TBPH) had Deferred Revenue of $125.00 thousand as of 2017-12-31, per its 10-K filed 2018-02-28.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current › Deferred Revenue, Current
us-gaap:DeferredRevenueCurrent · last filed 2018-02-28
- 2017-12-31: Deferred Revenue, Current $125.00K.
- 2017-09-30: Deferred Revenue, Current $134.00K.
- 2017-06-30: Deferred Revenue, Current $142.00K.
- 2017-03-31: Deferred Revenue, Current $142.00K.
| Period end | Deferred Revenue, Current |
|---|---|
| 2017-12-31 | $125.00K 10-K · filed 2018-02-28 |
| 2017-09-30 | $134.00K 10-Q · filed 2017-11-08 |
| 2017-06-30 | $142.00K 10-Q · filed 2017-08-09 |
| 2017-03-31 | $142.00K 10-Q · filed 2017-05-10 |
| 2016-12-31 | $152.00K 10-K · filed 2018-02-28 |
| 2016-09-30 | $218.00K 10-Q · filed 2016-11-09 |
| 2016-06-30 | $662.00K 10-Q · filed 2016-08-09 |
| 2016-03-31 | $1.12M 10-Q · filed 2016-05-10 |
| 2015-12-31 | $144.00K 10-K · filed 2017-03-01 |
| 2015-09-30 | $271.00K 10-Q · filed 2015-11-12 |
| 2015-06-30 | $342.00K 10-Q · filed 2015-08-13 |
| 2015-03-31 | $310.00K 10-Q · filed 2015-05-13 |
| 2014-12-31 | $89.00K 10-K · filed 2016-03-11 |
| 2014-09-30 | $667.00K 10-Q · filed 2014-11-12 |
| 2014-06-30 | $5.72M 10-Q · filed 2014-08-14 |
| 2014-06-02 | $6.69M 10-K · filed 2017-03-01 |
| 2014-03-31 | $7.73M 10-Q · filed 2014-06-24 |
| 2013-12-31 | $8.21M 10-K · filed 2015-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |